Novartis suspends eight CAR-T trials after three patient deaths
Novartis AG has reportedly suspended eight clinical trials of an experimental CAR-T treatment after three patients died, according to The Wall Street Journal. The trials were stopped after the company learned of the deaths in late August.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.